Beneficial vascular effects of oral phosphatidylserine supplementation in type 2 diabetes
Journal of Applied Physiology · 01.07.2026 · 141 (1) · 130-148
DOI: 10.1152/japplphysiol.00281.2026 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Applied Physiology, erschienen am 01.07.2026. Verfasst von Neil J McMillan und 16 weiteren Autor:innen. Beteiligte Einrichtung: NextGen Precision Health, University of Missouri, Columbia, Missouri, United States. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Phosphatidylserines. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Sao Paulo Research Foundation, American Heart Association (AHA), NHLBI NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The sheddase activity of a disintegrin and matrix metalloproteinase 17 (ADAM17) is augmented in the setting of type 2 diabetes (T2D), likely contributing to the shedding of the extracellular domain of the insulin receptor on the arterial endothelial surface, leading to endothelial dysfunction. Findings from this work support the notion that exogenous phosphatidylserine can inhibit arterial ADAM17 activity and improve markers of vascular health in diabetic mice and humans with diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NextGen Precision Health, University of Missouri, Columbia, Missouri, United States.
- Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, Missouri, United States.
- Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, Missouri, United States.
- Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, Missouri, United States.
- Instituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Division of Endocrinology and Metabolism, Department of Medicine, University of Missouri, Columbia, Missouri, United States.
ORCID-Profile: Neil J McMillan, Marc A Augenreich, Francisco I Ramirez-Perez, Olubodun M Lateef, Manikandan Nagarajan, Natnicha Imkaew, Yoskaly Lazo-Fernandez, Larissa Ferreira-Santos, Camila Manrique-Acevedo, Luis A Martinez-Lemus, Jaume Padilla
Förderung
- Sao Paulo Research Foundation
- American Heart Association (AHA)
- NHLBI NIH HHS
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
Zitieren
APA
McMillan, N. J., Augenreich, M. A., Ramirez-Perez, F. I., Power, G., Burr, K., Lateef, O. M., Nagarajan, M., Foote, C. A., Imkaew, N., Jurrissen, T. J., Lazo-Fernandez, Y., Betancourt-Cortes, E. E., Ferreira-Santos, L., Beltran-Ornelas, J. H., Manrique-Acevedo, C., Martinez-Lemus, L. A., & Padilla, J. (2026). Beneficial vascular effects of oral phosphatidylserine supplementation in type 2 diabetes. Journal of Applied Physiology, 141(1), 130-148. https://doi.org/10.1152/japplphysiol.00281.2026
Vancouver
McMillan NJ, Augenreich MA, Ramirez-Perez FI, Power G, Burr K, Lateef OM, et al. Beneficial vascular effects of oral phosphatidylserine supplementation in type 2 diabetes. Journal of Applied Physiology. 2026;141(1):130-148. doi:10.1152/japplphysiol.00281.2026
BibTeX
@article{McMillan2026,
author = {McMillan, Neil J and Augenreich, Marc A and Ramirez-Perez, Francisco I and Power, Gavin and Burr, Katherine and Lateef, Olubodun M and Nagarajan, Manikandan and Foote, Christopher A and Imkaew, Natnicha and Jurrissen, Thomas J and Lazo-Fernandez, Yoskaly and Betancourt-Cortes, Edgar E and Ferreira-Santos, Larissa and Beltran-Ornelas, Jesus H and Manrique-Acevedo, Camila and Martinez-Lemus, Luis A and Padilla, Jaume},
title = {Beneficial vascular effects of oral phosphatidylserine supplementation in type 2 diabetes},
journal = {Journal of Applied Physiology},
year = {2026},
volume = {141},
number = {1},
pages = {130--148},
doi = {10.1152/japplphysiol.00281.2026}
}
EUVIMED